Combination comprising a CDK inhibitor and a topoisomerase 1 inhibitor for the treatment of cancer and other proliferative diseases
AssigneeCyclacel Limited
InventorsAthos Gianella-Borradori, Marie-France Poupon
Life of this patent
Estimating the term…
Abstract
A first aspect of the invention relates to a combination comprising a CDK inhibitor and CPT-11. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and CPT-11 as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a CDK inhibitor and CPT-11 to a subject.
Claims35
A combination comprising CPT-11 and a CDK inhibitor.
A pharmaceutical composition comprising CPT-11, a CDK inhibitor and a pharmaceutically acceptable carrier, diluent or excipient.
A pharmaceutical product comprising CPT-11 and CDK inhibitor as a combined preparation for simultaneous, sequential or separate use in therapy.
A method of treating a proliferative disorder in a subject, said method comprising administering to said subject CPT-11 and a CDK inhibitor.
The method of claim:
- 1 3, wherein the CDK inhibitor is a 2,6,9-trisubstituted purine.
A method of preparing a pharmaceutical product for the treatment of a proliferative disorder, comprising combining CPT-11 and a CDK inhibitor in a preparation, such that the CPT-11 and the CDK inhibitor may be administered simultaneously, sequentially or separately.
A combination comprising a CDK inhibitor and a DNA topoisomerase 1 inhibitor.
A method of treating a proliferative disorder in a subject, said method comprising the steps of:
- (i) administering a DNA topoisomerase 1 inhibitor in an amount sufficient to increase CDK1 levels;
- and
- (ii) administering a CDK inhibitor in an amount sufficient to induce apoptosis.
Dependencies are inferred from the claim text.